Key Takeaways
- Steady quarter, cautious tone: Revenue grew 3.9% QoQ (18.8% YoY), the 21st straight quarter of growth, but management flagged slower decision-making and postponed wage hikes as a "cautionary measure."
- Healthcare vertical hit a soft patch: The vertical declined 2.1% QoQ due to a planned on-site to offshore transition at its largest client, creating a cost overlap that also pressured margins.
- AI platform pivot is now the strategy: Persistent launched SASVA 3.0 and structured its go-to-market around "AI for Technology" and "AI for Business," aiming to differentiate in larger deals without yet disclosing SASVA-influenced revenue.
- Margin levers are loaded but not yet pulled: EBIT margin held at 15.5% as ESOP tailwinds offset cost headwinds; management reiterated a 200-300 bps margin improvement target by FY27 and delayed wage hikes to protect near-term profitability.
- What to watch next quarter: Whether the healthcare transition costs clear as promised, any improvement in decision-making speed, and the actual rollout (or further delay) of the annual wage hike.
Demand Environment
- Growth is broad but decelerating: Constant-currency sequential growth slowed to 3.3% from a ~4.5% average, a deceleration management declined to characterize as a new normal, saying only "you can yourself do the math."
- Decision-making is the bottleneck: The pipeline is healthy but the environment is cautious; decision-making cycles have lengthened, and management explicitly warned not to expect a sudden windfall next quarter.
- Uncertainty continuum: Management cited a sequence of geopolitical shocks (India-Pakistan tensions, Iran situation, tariffs) that kept clients hesitant, making the order book dependent on decisions that are taking longer to materialize.
- Book-to-bill softened: The TCV-to-revenue ratio dropped to 1.3-1.4x from 1.5-1.6x over the last two quarters; management said they measure the executable order book and are "reasonably confident" but gave no target for recovery.
Kalra: "All I can say is, the environment has been cautious. Decision making has been slow. If the environment becomes a little bit better and not just for us, for everyone, I think things will be easier."
Vertical Performance
| Vertical | Trend | Commentary |
|---|---|---|
| BFSI | ▲ Strong growth | Led all verticals at 30.7% YoY; Persistent is brought in as a challenger to larger incumbents for AI discussions and optimizations; expected to lead growth this year. |
| Software & Hi-Tech | ▲ Solid growth | Grew 14.1% YoY; ranked second in expected growth contribution for the year. |
| Healthcare & Life Sciences | ▼ QoQ decline | Declined 2.1% QoQ due to planned on-site to offshore transition at the largest client; cost overlap from subcontractors staying flat while offshore headcount ramped pressured margins. Growth outside the top customer was sharp. |
| Europe | ▲ Strong geography | Led all regions with 37.5% YoY growth. |
| North America | ▲ Solid growth | Grew 17.4% YoY. |
| India | ▲ Solid growth | Grew 18.3% YoY. |
| Rest of World | ▼ Decline | Declined 1.7% YoY. |
- Healthcare outlook is cautiously constructive: Management expects no further degrowth and says healthcare will be a growth vertical this year, though not at the 30-60% YoY rates of last year. Tariff stress on equipment manufacturers and federal funding impacts (DOGE, USAID) are pushing clients toward cost-control plans, vendor consolidation, and more offshoring, which could create both headwinds and opportunities.
- BFSI vs. healthcare dynamics: BFSI will grow well this year; future growth depends on pipeline conversion. Healthcare faces a different dynamic: the largest client's vendor consolidation and offshore shift created a one-off drag, but the rest of the portfolio is growing.
Kalra: "Will it continue the growth at the 30%, 40%, 60% year-on-year that we had last year, may not be, but there'll be definitely growth in healthcare as well."
AI & Platform Strategy
- SASVA 3.0 is the centerpiece: The AI-powered digital engineering platform was upgraded and, as a "fun fact," was built leveraging SASVA itself. It now spans requirements, backlog grooming, coding, testing, release, support, and modernization.
- Two-pillar AI structure: "AI for Technology" targets engineering productivity and tech stack modernization for enterprise software companies; "AI for Business" focuses on making enterprises AI-ready and adopting agentic AI for processes, customer experiences, and workflows.
- SASVA as a competitive wedge: Even when clients do not buy SASVA-based services, the platform lands Persistent in a differentiated position, expanding the addressable market and helping win larger deals. Management declined to disclose SASVA-influenced bookings or revenue.
- No revenue deflation observed: Despite delivering significant productivity gains via SASVA in outsourced engagements, Persistent has not seen revenue deflation from existing customers. Regulated industries (healthcare, BFSI) are still experimenting with AI platforms, and adoption at scale will take time.
- Agentic AI in early production: Persistent built an underwriter agent on Salesforce Agentforce for loan origination and a SciMitra Agent on Google agentic platforms for healthcare life sciences.
Kalra: "Whether people buy SASVA or not, whether people SASVA-based services or not, it kind of lands us in a very good, competitive, differentiated position in our business."
Margins & Cost Structure
| Margin walk (QoQ) | Impact |
|---|---|
| Lower ESOP cost | +230 bps |
| Absence of earn-out reversal | –60 bps |
| Onsite retention & delayed ramp-ups | –100 bps |
| Higher amortization | –40 bps |
| Unfavorable currency | –40 bps |
| Net change → 15.5% | –10 bps |
- Wage hike postponed: The annual increase normally rolled out in July was delayed by one quarter as a cautionary measure due to market uncertainty; if conditions improve, management may compensate employees at year-end.
- Healthcare margin pressure was transitional: Margins in healthcare came off sequentially because of overlap costs from moving work offshore; headcount was added offshore but subcontractor cost remained flat, creating a temporary cost overlap that should normalize.
- Cost structure will stay lumpy: As Persistent wins larger deals, subcontractor costs onshore may come down over time but other costs will rise as new deals ramp up, creating a "flywheel motion" that management accepts as part of scaling.
- Margin ambition intact: Management remains confident in improving trading margin by 200-300 bps by FY27, with levers including pricing, utilization, and SG&A leverage. ESOP cost will remain flat for the next couple of quarters before declining further in FY27.
Kalra: "So, there is a little bit of uncertainty continuum that is happening and the order book is dependent on people taking decisions. So, as I said before, pipeline is good, we'll let it pan out. And as a cautionary measure to make sure that we are being prudent, we have delayed the increase by a quarter."
Deal Wins & Order Book
- Largest tech company win: Selected by one of the largest technology companies globally to replace a legacy on-prem data warehouse and analytics product reaching end of life; Persistent will build a modern AI-enabled solution and manage the software roadmap, hardware compatibility, and support under a revenue-sharing construct with significant multi-year opportunity.
- Global software quality leader: A 360-degree engagement including takeover of a cloud testing platform, extension of existing product engagements, and transformation using agentic AI; SASVA platform capabilities were instrumental in the win.
- US federal corporation (BFSI): Replacing a legacy debt issuance application with a scalable platform spanning UI/UX, DevOps, and system integration; deal was proactively sourced by showcasing AI capabilities via SASVA.
- UK banking and wealth management leader: Co-engineering the launch of a digital banking platform; digital banking expertise, partner ecosystem, SASVA, iAURA, and the Persistent Digital Banking Studio were key differentiators.
- Life sciences and scientific instrumentation player: Establishing a software center of excellence in India, won on strategic partnership and program governance capabilities.
- Global clinical research leader: Building a centralized Serious Adverse Event tracking and safety report distribution portal, leveraging pharma safety and clinical trial management expertise.
People & Organization
- Headcount growth tilted offshore: Sequential headcount additions over the last two quarters have been predominantly offshore, consistent with the margin management strategy.
- Utilization is running high: Management sees no reason to loosen utilization currently, calling it an easy lever to adjust if the supply-demand situation changes.
- Attrition uptick is industry-wide, not wage-linked: A slight uptick in attrition is attributed to GCCs being more active, product companies setting up captives, and large banks and enterprises hiring; management sees no correlation with the wage hike delay and no indication of much higher attrition ahead.
- CPO succession: Yogesh Patgaonkar retires effective July 31, 2025; Rajiv Nathani, who joined in February 2025, assumes the CPO role on August 1, 2025. A new CMO, Shimona Chadha, also joined, based in New Jersey.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue aspiration | Reach $2 billion in revenue through profitable, sustainable growth, "not at any cost" | By end of FY27 (March 2027) |
| Margin improvement | Improve trading margin by 200-300 bps | By FY27 |
| ESOP cost trajectory | Remain flat for next couple of quarters, then decline further | FY27 over FY26 |
| Healthcare vertical | No further degrowth expected; will be a growth vertical this year | FY26 |
| Wage hike | Delayed by one quarter; compensation decision at year-end if conditions improve | Q2 FY26 rollout / year-end compensation call |
| Effective tax rate | 22.5% to 23.5% full-year range | FY26 |
| Vertical focus | Deepen existing verticals (software/hi-tech, BFSI, healthcare/life sciences) before evaluating new ones | Next 1-3 years |
| Acquisition strategy | Capability-led, smaller tuck-in acquisitions; scaled acquisition only for a good European asset | Ongoing |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue (USD) | $389.7 million, +3.9% QoQ and +18.8% YoY |
| Revenue (INR) | ₹3,333.59 crore, +2.8% QoQ and +21.8% YoY |
| Constant currency revenue growth | 3.3% QoQ |
| EBIT margin | 15.5%, +150 bps YoY; net decrease of 10 bps QoQ after tailwinds and headwinds |
| EBIT (INR) | ₹517.81 crore, +2.5% QoQ and +34.8% YoY |
| Profit after tax (PAT) | ₹424.94 crore, +7.4% QoQ and +38.7% YoY; PAT margin 12.7% |
| Earnings per share | ₹27.4, +36.5% YoY |
| Total Contract Value (TCV) | $520.8 million; new bookings TCV $337.0 million |
| Annual Contract Value (ACV) | $385.3 million; ACV from new bookings $211.8 million |
| Book-to-bill ratio | 1.3–1.4 in the last two quarters, down from 1.5–1.6 historically (per an analyst's math) |
| North America revenue growth | 17.4% YoY in USD |
| Europe revenue growth | 37.5% YoY in USD |
| BFSI vertical revenue growth | 30.7% YoY |
| Software, Hi-tech & Emerging Industries revenue growth | 14.1% YoY |
| Healthcare & Life Sciences revenue growth | 12.4% YoY; -2.1% QoQ |
| Total headcount | 25,314, +1,821 YoY and +746 QoQ |
| Trailing 12-month attrition | 13.9%, up from 11.9% in Q1 last year |
| Return on Capital Employed (RoCE, excluding cash) | 43.8%, +510 bps YoY |
| Billed DSO | 56 days, improved 2 days QoQ |
| Operating cash flow to PAT | 98.6% |
| Effective tax rate | 23.5%; expected full-year range 22.5%–23.5% |
| Forward contracts outstanding | $440 million at average rate ₹86.90 per dollar |
| SASVA-related patents | 55-plus, up from 35 in Q4 FY25 |
| Annual wage hike | Postponed by a quarter from the usual July cycle |